Are there any trials on the combination of retatrutide (investigational medication) with mots-C (monoclonal antibody)

No Clinical Trials on Retatrutide + MOTS-C Combination Exist

There are currently no clinical trials investigating the combination of retatrutide with MOTS-C. Based on a comprehensive review of the available evidence, no studies have examined this specific combination therapy.

Understanding Retatrutide

• Retatrutide (LY3437943) is a novel triple-hormone-receptor agonist that targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors 1, 2
• It is being investigated primarily for obesity treatment, with significant weight loss results in clinical trials 2
• In phase 2 trials, retatrutide demonstrated dose-dependent weight reduction, with higher doses (8mg and 12mg) achieving 22.8-24.2% weight loss at 48 weeks 2
• At 48 weeks, 100% of participants on 8mg or 12mg doses achieved ≥5% weight loss, and 75-83% achieved ≥15% weight loss 1, 2

Retatrutide Clinical Development Status

• Retatrutide is still an investigational medication, not yet FDA-approved 3
• The most common adverse events in clinical trials were gastrointestinal (nausea, diarrhea, vomiting), typically mild to moderate in severity 2, 4
• Recent meta-analyses have confirmed retatrutide's significant effects on weight reduction, BMI, waist circumference, and metabolic parameters 5, 6
• Dose-dependent increases in heart rate were observed in clinical trials, peaking at 24 weeks and declining thereafter 2

Clinical Trial Considerations for Novel Combinations

• According to NCI guidelines, all phase 1 combination trials should state an explicit hypothesis justifying the combination, including a pharmacological or biological rationale supported by in vitro data, in vivo data, or clinical data 7
• The development of novel drug combinations requires careful consideration of the optimum selection of agents, appropriate dosing and scheduling, potential drug-drug interactions, and overlapping toxicities 7
• Priority should be given to combinations with the strongest rationale that are most likely to result in clinically significant therapeutic advances 7

Conclusion on Retatrutide + MOTS-C

• No clinical trials have investigated the combination of retatrutide with MOTS-C 1, 3, 2, 4, 5, 6
• Any future investigation of this combination would require establishing a clear biological or pharmacological rationale and addressing potential safety concerns before proceeding to clinical trials 7